Medicxi Ventures participates in €3.3 million investment in Yukin Therapeutics
Client(s) Medicxi Ventures (UK) LLP
Jones Day represented Medicxi Ventures (UK) LLP in connection with its €3.3 million (US$3.7 million) investment in Yukin Therapeutics, a French-based company engaged in the research and development of small molecules targeting the kinase NIK for the treatment of cancer and inflammatory diseases.